Travere Therapeutics (TVTX) Gains from Investment Securities (2013 - 2023)

Travere Therapeutics (TVTX) has 11 years of Gains from Investment Securities data on file, last reported at $1.8 million in Q2 2023.

• Quarterly Gains from Investment Securities fell 62.5% year-over-year to $1.8 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $570000.0 (down 96.2% YoY) and the FY2022 annual result came in at $15.0 million, down 32.59% from the prior year.
• Gains from Investment Securities grew to $1.8 million in Q2 2023, from -$2.3 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $13.9 million in Q3 2021 to a low of -$11.5 million in Q4 2019.
• A 5-year average of $1.2 million and a median of $404500.0 in 2019 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2020 — Gains from Investment Securities jumped 826.43% — and 2022, when it plunged 124.16%.
• Tracing TVTX's Gains from Investment Securities over 5 years: stood at -$11.5 million in 2019, then jumped by 81.37% to -$2.1 million in 2020, then grew by 18.65% to -$1.7 million in 2021, then decreased by 24.2% to -$2.2 million in 2022, then surged by 185.15% to $1.8 million in 2023.
• The last three Gains from Investment Securities figures came in at $1.8 million (Q2 2023), -$2.3 million (Q1 2023), and -$2.2 million (Q4 2022), per Business Quant data.